| abstract |
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, specifically to a method of treating osteoarthritis (OA). That is ensured by using a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist to reduce or prevent pathological osteoarthritis symptoms involving cartilage damage, osteophyte formation and joint deformation, where the antagonist is GM-CSF specific antibody.EFFECT: use of the given group of inventions enables using an antagonist of the granulocyte-macrophage colony-stimulating factor of treating osteoarthritis, particularly manifested osteoarthritis, caused by degenerative processes in the joint and not directly related to the inflammatory component.7 cl, 6 dwg, 9 ex |